BR112016006970A2 - enzalutamida em combinação com afuresertib para o tratamento de câncer - Google Patents

enzalutamida em combinação com afuresertib para o tratamento de câncer

Info

Publication number
BR112016006970A2
BR112016006970A2 BR112016006970A BR112016006970A BR112016006970A2 BR 112016006970 A2 BR112016006970 A2 BR 112016006970A2 BR 112016006970 A BR112016006970 A BR 112016006970A BR 112016006970 A BR112016006970 A BR 112016006970A BR 112016006970 A2 BR112016006970 A2 BR 112016006970A2
Authority
BR
Brazil
Prior art keywords
chloro
afuresertib
enzalutamide
combination
methyl
Prior art date
Application number
BR112016006970A
Other languages
English (en)
Inventor
J Cornfeld Mark
Kumar Rakesh
Renae Morris Shannon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112016006970A2 publication Critical patent/BR112016006970A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

a presente invenção refere-se a uma nova combinação que compreende um inibidor de receptor de androgênio, por exemplo: 4-(3-(4-ciano-3-(trifluorometil)fenil)-5,5-dimetil-4-oxo-2-tioxoimidazolidin-1-il)-2-fluoro-n-metilbenzamida ou um sal farmaceuticamente aceitável da mesma e um composto que inibe akt, por exemplo: n-{(1s)-2-amino-1-[(3-fluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tifenocarboxamida ou um sal farmaceuticamente aceitável da mesma e agentes antineoplásicos adicionais opcionais; composições farmacêuticas que compreendem os mesmos e métodos de utilização de tais combinações e composições no tratamento de estados de saúde em que a inibição de receptor de androgênio e/ou a inibição de akt é benéfica, por exemplo, câncer.
BR112016006970A 2013-10-01 2014-10-01 enzalutamida em combinação com afuresertib para o tratamento de câncer BR112016006970A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361885053P 2013-10-01 2013-10-01
US201461935404P 2014-02-04 2014-02-04
PCT/IB2014/064997 WO2015049650A1 (en) 2013-10-01 2014-10-01 Enzalutamide in combination with afuresertib for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112016006970A2 true BR112016006970A2 (pt) 2017-08-01

Family

ID=51830566

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016006970A BR112016006970A2 (pt) 2013-10-01 2014-10-01 enzalutamida em combinação com afuresertib para o tratamento de câncer

Country Status (11)

Country Link
US (3) US20160235714A1 (pt)
EP (1) EP3052098B1 (pt)
JP (2) JP6355724B2 (pt)
KR (1) KR101797415B1 (pt)
CN (1) CN106061481B (pt)
AU (1) AU2014330780B2 (pt)
BR (1) BR112016006970A2 (pt)
CA (1) CA2923899A1 (pt)
MX (1) MX2016004265A (pt)
RU (1) RU2016116789A (pt)
WO (1) WO2015049650A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103298345B (zh) 2011-01-11 2016-12-14 诺瓦蒂斯公司 组合
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
ES2900149T3 (es) 2016-07-21 2022-03-16 Hadasit Med Res Service Combinaciones que comprenden antagonistas o inhibidores de AR para su uso en el tratamiento del glioblastoma
US20200345692A1 (en) * 2018-01-19 2020-11-05 Indiana University Research And Technology Corporation Therapeutic targeting of receptor tyrosine kinase inhibitor-induced androgen receptor phosphoryation in cancer
JP6545349B1 (ja) * 2018-07-18 2019-07-17 株式会社 ディー・エヌ・エー ライブ動画を配信するためのシステム、方法、及びプログラム
CN112022833B (zh) * 2020-11-05 2021-02-12 上海翰森生物医药科技有限公司 一种恩杂鲁胺药物组合物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
RU2008143554A (ru) * 2006-04-05 2010-05-10 Новартис АГ (CH) Комбинации терапевтических агентов для лечения рака
DK2061561T3 (da) * 2006-08-25 2013-10-07 Janssen Oncology Inc Sammensætninger til behandling af cancer
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EA018907B1 (ru) 2009-01-30 2013-11-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Кристаллический гидрохлорид n-{(1s)-2-амино-1-[(3-фторфенил)метил]этил}-5-хлор-4-(4-хлор-1-метил-1h-пиразол-5-ил)-2-тиофенкарбоксамида
EP2704699A1 (en) 2011-05-03 2014-03-12 University of Rochester Methods for treating prostate cancer
JP6091510B2 (ja) * 2011-10-10 2017-03-08 ザック システム １７−置換ステロイドの製造方法
SG11201401471PA (en) * 2011-11-30 2014-08-28 Astrazeneca Ab Combination treatment of cancer

Also Published As

Publication number Publication date
KR101797415B1 (ko) 2017-11-13
AU2014330780A1 (en) 2016-03-24
RU2016116789A3 (pt) 2018-07-12
CA2923899A1 (en) 2015-04-09
MX2016004265A (es) 2016-07-08
AU2014330780B2 (en) 2017-05-25
CN106061481B (zh) 2019-08-16
US20160235714A1 (en) 2016-08-18
EP3052098A1 (en) 2016-08-10
JP2018135331A (ja) 2018-08-30
RU2016116789A (ru) 2017-11-09
US20180117011A1 (en) 2018-05-03
KR20160058184A (ko) 2016-05-24
JP6355724B2 (ja) 2018-07-11
JP2016531881A (ja) 2016-10-13
CN106061481A (zh) 2016-10-26
WO2015049650A1 (en) 2015-04-09
EP3052098B1 (en) 2020-12-02
US20180344699A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
BR112016006970A2 (pt) enzalutamida em combinação com afuresertib para o tratamento de câncer
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
BR112018070677A2 (pt) inibidores de mcl-1 macrocíclicos para o tratamento de câncer
MX2018000512A (es) Compuestos de indazaol y azaindazol como inhibidores de la cinasa 4 asociada al receptor de interlucina 1 (irak-4).
GEP20217316B (en) Aromatic sulfonamide derivatives
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
BR112019002576A2 (pt) composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
BR112015016793A2 (pt) compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim
GEP20166484B (en) Protein kinase inhibitors
BR112018010873A2 (pt) compostos e métodos para inibir a produção de trimetilamina
BR112020016020A8 (pt) Inibidor de atr e aplicação do mesmo
PH12016502353A1 (en) Pharmaceutical composition
BR112016028814A2 (pt) ?composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição de reações imunitárias ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, composto, um sal, um isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, de um sal, de um isômero, ou de uma mistura farmaceuticamente aceitável do mesmo?
MX2017001620A (es) Formas cristalinas de inhibidores de glutaminasa.
BR112019003710A2 (pt) inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7.
DOP2016000120A (es) Nuevos inhibidores de dgat2
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2534 DE 30-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.